This study is for patients who have been diagnosed with head and neck squamous cell carcinoma (HNSCC) that has returned (recurrent) or spread after previous treatment (metastatic). The investigational drug in this study is Buparlisib (AN2025) that will be given in combination with Paclitaxel (an approved drug). The study will also use alone.

The main purpose of this research study is to assess the effectiveness and safety of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone head and neck cancer that has progressed after prior immunotherapy (treatment that uses your immune system to attack your cancer, such as antiPD1/antiPDL1 treatments) with or without prior platinum-based chemotherapy. Participants can expect to be on this study for about 5 years.

This study is for patients who have been diagnosed with non-small cell lung cancer (NSCLC). The investigational drug in this study is sotorasib. Investigational means it is not approved by the United States Food and Drug Administration (US FDA). Sotorasib is an anti cancer drug that is being developed for tumors with a specific mutation called Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C. The purpose of this study is to find out if sotorasib has any anti-tumor effect and how safe (including side effects) it is in subjects with stage 4 NSCLC with a KRASG12C mutation. This drug is a tablet taken by mouth once a day. Participants can expect to receive treatment approximately 6 to 12 months including about 48 clinic visits followed by 5 years of follow-up.

This study is for subjects that have been diagnosed with advanced solid cancer tumors or relapsed prostate cancer. The investigational drugs in this study are hydroxychloroquine, nelfinavir, metformin, dasatinib and sirolimus. The purpose of this study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of cancer. Subjects can expect to be in this study for about 2.5 years.

This study is for participants that have a solid tumor that hasn't responded to previous treatment or has spread to other parts of the body (metastatic), including ovarian, cervical, endometrial, head and neck, squamous cell lung, kidney, prostate, colorectal, gastric, breast, bladder cancer, lung adenocarcinoma, or melanoma. This research study is for the investigational drug called TTX-080. This drug has not been approved by the United States Food and Drug Administration (FDA). This purpose of this study is to see what effects TTX-080 has on tumors. TTX-080 may help the immune system attack cancer cells. The study drug is given intravenously (into the vein). It is expected that participants could be in the study for about 2 years and will depend on how he/she tolerate the study drug. Participants may experience certain side effects and discomforts from taking TTX-080. Because the study drug is experimental, all the side effects may not be known.

This study is for subjects that have been diagnosed with diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) for which they previously have received treatment, but the disease is worsening or has come back and no standard approved treatment options are available to them. This study is testing an "investigational" (not yet FDA- Food and Drug Administration- approved drug) study drug called GEN3009 (DuoHexaBody®-CD37). The purpose of one arm of the study is to find out if and how well the GEN3009 works against a subject's cancer (this is called the dose expansion part). The primary purpose of the second arm of the study is to determine the maximum tolerated dose (the highest dose of the drug that does not cause unacceptable side effects) with and/or determine the recommended dose of the study drug for the next phase of studies for this drug, as well as to evaluate the safety and tolerability of the study drug (this is called the dose escalation part). The subject may be seen up to once a week during this study. The subject may remain in the study for up to five years.

This study is for patients who have been diagnosed with metastatic Non-Small Cell Lung Cancer (NSCLC). The investigational drug in this study is BA3011. Investigational means the drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA). Participants will receive BA3011 by intravenous (IV) infusion. The purpose of this study is to understand how BA3011 works with and without nivolumab in fighting cancer cells; to see what side effects BA3011 has when given alone and in combination with nivolumab; to understand how the body absorbs and processes BA3011; and to understand whether BA3011, alone or in combination with nivolumab, causes a response by the immune system that leads to the development of antibodies (proteins made in the body that respond to a substance that is foreign to the body). Participants can expect to be in this study for about 2 and a half years.

This study is for patients who have been diagnosed with non-small cell lung cancer. The investigational drug in this study is BA3021. Investigational means the drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA). Participants will receive BA3021 by intravenous (IV) infusion. The purpose of this study is to see how BA3021 alone, and in combination with another drug called nivolumab, affects growth and formation of tumors; to see how safe BA3021 is alone and in combination with nivolumab; to understand how the body absorbs and processes BA3011; to understand whether BA3011, alone or in combination with nivolumab, causes a response by the immune system that leads to the development of antibodies (proteins made in the body that respond to a substance that is foreign to the body) which may prevent the study drug from working and/or increase your risk of side effects. Participants can expect up to 75 clinic visits over a period of about 3 years.

The purpose of this study is to understand if CX-2009 when given by itself to participants with advanced breast cancer is safe and has anti-tumor activity. CX-2009 will be combined with CX-072 to understand if the combination of these two drugs is safe and has anti-tumor activity in participants with advanced triple negative breast cancer.

This study is enrolling participants with advanced solid tumors. The purpose of the study is to see how safe the study drug UCB6114 is and how the body processes the drug when given alone or in combination with selected standard of care (SOC) regimens. Participants will receive UCB6114 via intravenous (IV; injected into a vein) infusion (drip) every 2 weeks, on Days 1 and Day 15 of each treatment cycle. If they continue to additional cycles, the infusions will continue to take place every 2 weeks according to the same schedule. Participants will be in this trial for a planned period of at least 2 cycles of study treatment (around 8 weeks) but should the Study Doctor decide that he/she is benefiting from treatment, he/she can remain in the study for additional cycles of treatment until he/she decide to withdraw from the study, he/she experiences any unacceptable side effects due to the treatment or if the disease worsens.

This study is for subjects that have relapsed or refractory follicular lymphoma, which means your lymphoma has worsened after treatment or has not responded to treatment. This study is testing an "investigational" (not yet FDA approved drug) study drug called loncastuximab tesirine (ADCT-402). Treatment will be administered intravenously or via tablet depending on the subject's assigned treatment. The primary purpose of this study is to test whether the investigational drug called loncastuximab tesirine may be more effective treatment for relapsed or refractory follicular lymphoma than treatment with the drug idelalisib. The subject will be seen approximately once every three weeks, and may remain in the study for up to 3 years.